MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men

NATICK, Massachusetts and NICE, France, June 18, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced
results from a sub-analysis of the MADIT-CRT trial data that showed women
received a greater clinical benefit from its cardiac resynchronization
therapy defibrillators (CRT-Ds) than men. The results were presented during
the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of
Cardiology and Director of the Al-Sabah Arrythmia Institute, St.
Luke's-Roosevelt Hospital Center, New York.

The sub-analysis demonstrated that both men and women
experienced significant benefit from cardiac resynchronization therapy.
However, women experienced a 70 percent reduction in heart failure events
compared to a 35 percent reduction for men. Additional analysis demonstrated
that women with asymptomatic or mild heart failure experienced a 72 percent
reduction in all-cause mortality.

"There are a number of factors that may explain why women
experienced a greater benefit than men," said Arthur Moss, M.D., Professor of
Medicine at the University of Rochester Medical Center and Principal
Investigator of the MADIT-CRT trial. "CRT-D therapy is designed to improve
the heart's overall pumping ability and women are more likely than men to
have non-ischemic heart disease, which typically affects the entire heart
rather than a single region and can lead to reduced pumping strength,
abnormal heart rhythms and disturbances in the heart's electrical system. Men
are more likely to have ischemic heart disease, also known as coronary artery
disease, which often leads to a more localized impact on the heart."

"These findings are noteworthy because CRT-D therapy has
historically been underutilized in women compared to men with the same level
of heart disease," said Kenneth Stein, M.D., Chief Medical Officer, CRM, for
Boston Scientific's Cardiology, Rhythm and Vascular Group. "Boston Scientific
believes that all patients should have equal access to high-quality
cardiovascular care regardless of gender. We believe these findings will help
reduce treatment disparities between men and women."

MADIT-CRT is the world's largest randomized CRT-D study of New
York Heart Association (NYHA) Class I and II patients[1], with more than
1,800 patients enrolled at 110 centers worldwide. Results of the MADIT-CRT
trial were published in the October 2009 issue of the New England Journal of
Medicine. Boston Scientific currently has an application under review with
the U.S. Food and Drug Administration for the expansion of its CRT-D
indication to include high-risk[2] NYHA Class I and II patients with Left
Bundle Branch Block.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements regarding
our product performance, clinical outcomes, regulatory approval of our
products, and our growth strategy. If our underlying assumptions turn out to
be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect
our ability to implement our business strategy and may cause actual results
to differ materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

———————————

[1] The NYHA clinical classifications of heart failure rank patients as
Class I-II-III-IV, according to the degree of symptoms or functional limits,
from asymptomatic to bed ridden. MADIT-CRT patients are asymptomatic or
mildly symptomatic, NYHA Class I (ischemic) and Class II (ischemic and
non-ischemic).

[2] High-risk is defined as QRS width >130 milliseconds with Left
Ventricular Ejection Fraction < 30 percent and Left Bundle Branch Block
(LBBB). LBBB is a condition in which the activation of the left ventricle is
delayed. As a result, portions of the left ventricle contract later than the
rest of the left ventricle and right ventricle, reducing the heart's pumping
ability.

    Contact:

    Paul Donovan
    +1-508-650-8541 (office)
    +1-508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    David Knutson
    +1-651-582-6574 (office)
    +1-651-260-8288 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    +1-508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation

Contact: Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile), Media Relations, Boston Scientific Corporation; David Knutson, +1-651-582-6574 (office), +1-651-260-8288 (mobile), Media Relations, Boston Scientific Corporation; Larry Neumann, +1-508-650-8696 (office), Investor Relations, Boston Scientific Corporation